What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

被引:79
|
作者
Petrini, P [1 ]
机构
[1] Karolinska Hosp, Dept Paediat, S-17176 Stockholm, Sweden
关键词
haemophilia; prophylaxis; trough level;
D O I
10.1046/j.1365-2516.2001.00471.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to prevent arthropathy, prophylaxis has to start at a young age before recurrent joint bleedings have taken place. The use of central venous lines has facilitated an early beginning to treatment, but due to side-effects, most European paediatricians prefer peripheral injections whenever possible. By starting primary prophylaxis at the age of 1-2 years with one injection weekly, the need for surgical implants may be reduced. In this study, only four of 34 boys born 1988-98 with severe haemophilia A or B needed a Port-a-Cath(R) for primary prophylaxis. Trough levels were measured in these patients and 79% showed a trough level < 1%, while 21% reached a level > 1%. Despite this, joint bleedings during 1998 were rare in both groups [0-4] and 59% of the boys with trough levels < 1% did not report any haemartroses during that year. Mean annual joint bleedings were the same in both groups [0.70, 0.71]. The lowest effective level of factors VIII and IX must be determined individually for each patient on primary or secondary prophylaxis.
引用
收藏
页码:99 / 102
页数:4
相关论文
共 50 条
  • [1] High dosage prophylactic treatment of severe patients with haemophilia B
    Plyusch, O.
    Kumskova, M.
    Velichko, I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 673 - 673
  • [2] When should prophylactic treatment in patients with haemophilia A and B start? - The German experience
    Kreuz, W
    Escuriola-Ettingshausen, C
    Funk, M
    Schmidt, H
    Kornhuber, B
    HAEMOPHILIA, 1998, 4 (04) : 413 - 417
  • [3] Prophylactic treatment of patients with haemophilia A or haernophilia B
    Engelfriet, CP
    Reesink, HW
    VOX SANGUINIS, 2005, 88 (01) : 62 - 67
  • [4] Impact of Adherence on Outcomes of Prophylactic Treatment in Severe Haemophilia Patients
    O'Hara, J.
    Miners, A.
    Elnoursi, A.
    Tordrup, D.
    Myren, K.
    HAEMOPHILIA, 2017, 23 : 81 - 81
  • [5] New approach for prophylactic treatment of severe adult patients with haemophilia A
    Plyusch, O.
    Kumskova, M.
    Kopylov, K.
    Velichko, I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 680 - 680
  • [6] The influence of prophylactic factor VIII in severe haemophilia A
    Gissel, M.
    Whelihan, M. F.
    Ferris, L. A.
    Mann, K. G.
    Rivard, G. E.
    Brummel-Ziedins, K. E.
    HAEMOPHILIA, 2012, 18 (02) : 193 - 199
  • [7] The impact of prophylactic treatment on children with severe haemophilia
    Liesner, RJ
    Khair, K
    Hann, IM
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) : 973 - 978
  • [8] Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment
    Andersson, Nadine G.
    Auerswald, Guenter
    Barnes, Chris
    Carcao, Manuel
    Dunn, Amy L.
    Fijnvandraat, Karin
    Hoffmann, Marianne
    Kavakli, Kaan
    Kenet, Gili
    Kobelt, Rainer
    Kurnik, Karin
    Liesner, Ri
    Makipernaa, Anne
    Manco-Johnson, Marilyn J.
    Mancuso, Maria E.
    Molinari, Angelo C.
    Nolan, Beatrice
    Perez Garrido, Rosario
    Petrini, Pia
    Platokouki, Helen E.
    Shapiro, Amy D.
    Wu, Runhui
    Ljung, Rolf
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (02) : 298 - 307
  • [9] Prophylactic Treatment of Severe Haemophilia A Patients with Inhibitors to FVIII with Peglip-FVIII
    Timofeeva, Margarita
    Zozulya, Nadezhda I.
    Pospelova, Tatiana
    Kosinova, Marina V.
    Kurtov, Igor
    Tuddenham, Edward
    Ling, Gavin
    BLOOD, 2021, 138
  • [10] Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII
    Tuddenham, Edward
    Wolf-Garraway, Richard
    Ling, Gavin
    BLOOD, 2022, 140 : 5617 - 5618